Zigakibart clinical trials
Also written BION-1301 and FUB523.
How each study uses zigakibart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the zigakibart studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2017 (1)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Novartis Pharmaceuticals (4) · Chinook Therapeutics, Inc. (2)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test zigakibart, phase 3 first.
- Aug 2027A Study of Zigakibart in Adults With IgA NephropathyPhase 3 · Novartis Pharmaceuticals
Studies
Open first, then newest update. How each study uses zigakibart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study to Assess the Effects of Zigakibart on IgA Nephropathy.RecruitingPhase 2Novartis PharmaceuticalsNCT07146906Written as zigakibart
- Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.RecruitingPhase 3Novartis PharmaceuticalsNCT06858319Written as zigakibart
- Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)CompletedPhase 1/2Novartis PharmaceuticalsNCT03945318Written as BION-1301 Single Dose
- A Study of Zigakibart in Adults With IgA NephropathyActive, not recruitingPhase 3Novartis PharmaceuticalsNCT05852938Written as BION-1301
- Open-label Safety and PK Study of BION-1301 in Japanese Healthy SubjectsCompletedPhase 1Chinook Therapeutics, Inc.NCT05508204Written as BION-1301
- Safety and Tolerability of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma (MM)TerminatedPhase 1/2Chinook Therapeutics, Inc.NCT03340883Written as BION-1301
Given beside what is tested · 2 — zigakibart is usual care or a partner of the new treatment
- A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA NephropathyNot yet recruitingPhase 3Novartis PharmaceuticalsNCT07850752Written as zigakibart
- Atrasentan in Patients With IgA NephropathyActive, not recruitingPhase 3Novartis PharmaceuticalsNCT04573478Written as Zigakibart
Codes
What other systems call zigakibart · ClinicalTrials.gg INT018366
- UNII (FDA) WM18Z62RTIZIGAKIBARTOne source FDA
- NCI Thesaurus C142822ZigakibartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | WM18Z62RTI | ZIGAKIBART | One source FDA |
| NCI Thesaurus | C142822 | Zigakibart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.